Geode Capital Management
PTHS

Geode Capital Management’s Pelthos Therapeutics PTHS Stock Holding History

Geode Capital Management’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Buy
15,290
+1,665
+12% +$39.5K ﹤0.01% 3749
2025
Q4 		$422K Buy
13,625
+3,295
+32% +$95K ﹤0.01% 3653
2025
Q3 		$289K Buy
10,330
+9,286
+889% +$225K ﹤0.01% 3809
2025
Q2 		$14.1K Buy
1,044
+37
+4% +$447 ﹤0.01% 4402
2025
Q1 		$14.3K Buy
+1,007
New +$17.2K ﹤0.01% 4406

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Geode Capital Management's PTHS Position: Q1 2026 in Review

Geode Capital Management increased its Pelthos Therapeutics (PTHS) stake by 12% in Q1 2026, buying an estimated $39.5K and bringing the position to 15,290 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #3749.

Geode Capital Management first reported a position in PTHS in Q1 2025 and has held it in 5 quarters since. The position peaked at $422K in Q4 2025. 17 funds tracked by Wall St. Rank hold PTHS as of Q1 2026.

  • Geode Capital Management held 15,290 shares of Pelthos Therapeutics worth $321K as of Q1 2026.
  • Geode Capital Management bought 1,665 Pelthos Therapeutics shares in Q1 2026, an estimated $39.5K.
  • Pelthos Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3749 holding.
  • Geode Capital Management first reported a position in Pelthos Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Geode Capital Management's Pelthos Therapeutics position peaked at $422K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.